Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mydecine Innovations Group Inc (OP: MYCOF )

0.0069 +0.0016 (+30.19%)
Streaming Delayed Price Updated: 3:56 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mydecine Innovations Group Inc

< Previous 1 2 3 Next >
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
Via Benzinga
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
--News Direct-- 
Via News Direct
Mydecine Reports Financial Results For 2021
  
Via Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution 
Via Benzinga
Exposures Product Safety
Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
Novel psychedelic-based drugs biotech Mydecine Innovations Group, Inc. (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA) completed its admission to Access segment of the UK’s stock market, AQSE Growth... 
Via Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
Novel psychedelic-based drugs biotech Mydecine Innovations Group (OTC: MYCOF) shared its financial results for the six months ended June 30, 2023. Second quarter of FY2023 looks like this: Cash... 
Via Benzinga
Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
Rose Hill, a Jamaica-based cultivator, supplier and exporter of premium psilocybin products and biomass to research partners and brands is now offering its first wellness retreat program under the name... 
Via Benzinga
Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
Colorado-based next-generation psychedelics biotech Mydecine Innovations Group Inc. (OTC: MYCOF) announced that, in connection with its common share subscription agreement with a third-party investor... 
Via Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) shared its condensed interim (unaudited) financial results for three months ended March 31, 2023. First quarter numbers:  
Via Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs. So far, Mydecine's compounds show promising... 
Via Benzinga
Mydecine: 2022 Financials & Business Update By Next-Gen Psychedelics Producer, Smoke Cessation Trial And More
Colorado and Leiden-based biotech company Mydecine Innovations Group (OTC: MYCOF) has shared its financial results and business highlights for the period ended December 31, 2022. In ciphers: 
Via Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
What a year for psychedelics! 
Via Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Mydecine Innovations Group Inc. 
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Mydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business... 
Via Benzinga
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
In connection with recent stock splits, psychedelics biotech Clearmind Medicine Inc. 
Via Benzinga
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC: MYCOF) reported its financial results. For the period corresponding to the six months ended June 30,... 
Via Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications. 
Via Benzinga
Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product. 
Via Benzinga
Mydecine Announces 1-for-50 Reverse Stock Split
The board of directors of Mydecine Innovations Group Inc. (OTCPK:MYCOF) voted in favor of completing a reverse stock split. With this action, the company will consolidate all issued and outstanding... 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,... 
Via Benzinga
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the... 
Via Talk Markets
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.